Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators. Zeuzem S, et al. Among authors: flisiak r. N Engl J Med. 2014 May 22;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. Epub 2014 May 4. N Engl J Med. 2014. PMID: 24795201 Free article. Clinical Trial.
Effectiveness and safety of direct-acting antivirals in the therapy of HCV-infected elderly people.
Brzdęk M, Zarębska-Michaluk D, Tomasiewicz K, Tudrujek-Zdunek M, Lorenc B, Mazur W, Berak H, Janocha-Litwin J, Klapaczyński J, Sitko M, Janczewska E, Dybowska D, Parfieniuk-Kowerda A, Piekarska A, Jaroszewicz J, Flisiak R. Brzdęk M, et al. Among authors: flisiak r. Minerva Med. 2024 Apr 9. doi: 10.23736/S0026-4806.24.09238-3. Online ahead of print. Minerva Med. 2024. PMID: 38591836
Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure.
Tronina O, Brzdęk M, Zarębska-Michaluk D, Lorenc B, Janocha-Litwin J, Berak H, Sitko M, Dybowska D, Mazur W, Tudrujek-Zdunek M, Janczewska E, Klapaczyński J, Dobracki W, Parfieniuk-Kowerda A, Krygier R, Socha Ł, Flisiak R. Tronina O, et al. Among authors: flisiak r. Clin Exp Hepatol. 2023 Dec;9(4):320-334. doi: 10.5114/ceh.2023.133307. Epub 2023 Dec 15. Clin Exp Hepatol. 2023. PMID: 38774196 Free PMC article.
Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients.
Piekarska A, Berkan-Kawińska A, Berak H, Mazur W, Sitko M, Parfieniuk-Kowerda A, Lorenc B, Dybowska D, Janczewska E, Janocha-Litwin J, Dobracka B, Socha Ł, Tudrujek-Zdunek M, Flisiak R. Piekarska A, et al. Among authors: flisiak r. Expert Rev Anti Infect Ther. 2024 May 16:1-6. doi: 10.1080/14787210.2024.2353691. Online ahead of print. Expert Rev Anti Infect Ther. 2024. PMID: 38722307
Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes.
Rzymski P, Niedziela J, Poniedziałek B, Rosińska J, Zarębska-Michaluk D, Sobala-Szczygieł B, Flisiak R, Gąsior M, Jaroszewicz J. Rzymski P, et al. Among authors: flisiak r. Virology. 2024 May 23;596:110118. doi: 10.1016/j.virol.2024.110118. Online ahead of print. Virology. 2024. PMID: 38805803 Free article.
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.
Dobrowolska K, Brzdęk M, Rzymski P, Flisiak R, Pawłowska M, Janczura J, Brzdęk K, Zarębska-Michaluk D. Dobrowolska K, et al. Among authors: flisiak r. Expert Opin Pharmacother. 2024 May 27:1-20. doi: 10.1080/14656566.2024.2358139. Online ahead of print. Expert Opin Pharmacother. 2024. PMID: 38768013 Review.
464 results